A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

Trial Profile

A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Feb 2018

At a glance

  • Drugs Sapacitabine (Primary) ; Decitabine
  • Indications Acute myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms SEAMLESS
  • Sponsors Cyclacel Pharmaceuticals
  • Most Recent Events

    • 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 12 Dec 2017 According to a Cyclacel Pharmaceuticals media release, the company is planning to discuss the data from this trial with European and US regulatory authorities and intends to provide updates as appropriate.
    • 12 Dec 2017 According to a Cyclacel Pharmaceuticals media release, data were reported at the 59th American Society of Hematology Annual Meeting 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top